Literature DB >> 21475236

The bone and beyond: 'Dem bones' are made for more than walking.

L Darryl Quarles1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21475236      PMCID： PMC5079528          DOI： 10.1038/nm0411-428

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  16 in total

Review 1.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

2.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

3.  Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.

Authors:  Fumie Saji; Takashi Shigematsu; Toshifumi Sakaguchi; Masaki Ohya; Hikari Orita; Yuka Maeda; Maki Ooura; Toru Mima; Shigeo Negi
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-25

4.  Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice.

Authors:  Kiyomi Tsuji; Toyonobu Maeda; Tetsuya Kawane; Ayako Matsunuma; Noboru Horiuchi
Journal:  J Bone Miner Res       Date:  2010-08       Impact factor: 6.741

5.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

Authors:  Shiguang Liu; Wen Tang; Jianping Zhou; Jason R Stubbs; Qiang Luo; Min Pi; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

6.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Authors:  Orlando Gutierrez; Tamara Isakova; Eugene Rhee; Anand Shah; Julie Holmes; Gina Collerone; Harald Jüppner; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

7.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

Authors:  Tetsuhiko Sato; Yoshihiro Tominaga; Tsuneo Ueki; Norihiko Goto; Susumu Matsuoka; Akio Katayama; Toshihito Haba; Kazuharu Uchida; Shohei Nakanishi; Junichiro James Kazama; Fumitake Gejyo; Takeyoshi Yamashita; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

9.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

10.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741
View more
  21 in total

Review 1.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

Review 2.  Regulation of Long Bone Growth in Vertebrates; It Is Time to Catch Up.

Authors:  Alberto Roselló-Díez; Alexandra L Joyner
Journal:  Endocr Rev       Date:  2015-10-20       Impact factor: 19.871

Review 3.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

Review 4.  Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Exp Cell Res       Date:  2012-03-07       Impact factor: 3.905

5.  Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues.

Authors:  Ryan P Downs; Zhousheng Xiao; Munachi O Ikedionwu; Jacob W Cleveland; Ai Lin Chin; Abigail E Cafferty; L Darryl Quarles; Jesse D Carrick
Journal:  Bioorg Med Chem       Date:  2020-11-18       Impact factor: 3.641

6.  Ensemble docking to difficult targets in early-stage drug discovery: Methodology and application to fibroblast growth factor 23.

Authors:  Hector A Velazquez; Demian Riccardi; Zhousheng Xiao; Leigh Darryl Quarles; Charless Ryan Yates; Jerome Baudry; Jeremy C Smith
Journal:  Chem Biol Drug Des       Date:  2017-11-03       Impact factor: 2.817

7.  FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.

Authors:  Zhousheng Xiao; Gwendalyn King; Salvatore Mancarella; Undral Munkhsaikhan; Li Cao; Chun Cai; Leigh Darryl Quarles
Journal:  JCI Insight       Date:  2019-12-05

8.  Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study.

Authors:  Romina di Giuseppe; Tilmann Kühn; Frank Hirche; Brian Buijsse; Jutta Dierkes; Andreas Fritsche; Rudolf Kaaks; Heiner Boeing; Gabriele I Stangl; Cornelia Weikert
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

9.  Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol.

Authors:  Hala Alshayeb; Arif Showkat; Barry M Wall; Geeta G Gyamlani; Valentin David; L Darryl Quarles
Journal:  J Clin Endocrinol Metab       Date:  2014-06-24       Impact factor: 5.958

Review 10.  Novel bone endocrine networks integrating mineral and energy metabolism.

Authors:  Min Pi; L Darryl Quarles
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.